Emergent BioSolutions (EBS) Misses Q4 EPS by 81c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.44 --0%
Financial Fact:
Earnings per share - basic: 0.52
Today's EPS Names:
CRVL, DD, ARDS, More
Financial Fact:
Earnings per share - basic: 0.52
Today's EPS Names:
CRVL, DD, ARDS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.43), $0.81 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $148.7 million versus the consensus estimate of $237 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aptiv (APTV) Tops Q3 EPS by 9c; offers guidance
- Columbus McKinnon (CMCO) Tops Q2 EPS by 23c ; Offers Guidance
- Ferrari N.V (RACE) Tops Q3 EPS by 13c; upgrades guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
